General Information of Drug Combination (ID: DCCG3DH)

Drug Combination Name
Sorbitol Lamivudine
Indication
Disease Entry Status REF
Infection, Human Immunodeficiency Virus Phase 4 [1]
Component Drugs Sorbitol   DMAN0DE Lamivudine   DMI347A
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sorbitol
Disease Entry ICD 11 Status REF
Constipation DD91.1 Approved [2]
Sorbitol Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Sorbitol dehydrogenase (SORD) DEWU03P DHSO_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Sorbitol Interacts with 13 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Sorbitol dehydrogenase (SORD) OTC44CR6 DHSO_HUMAN Increases Abundance [7]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [8]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [8]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [8]
MAP kinase-activated protein kinase 2 (MAPKAPK2) OT460SBO MAPK2_HUMAN Increases Activity [9]
Mitogen-activated protein kinase 12 (MAPK12) OTTCKE27 MK12_HUMAN Increases Phosphorylation [5]
Mitogen-activated protein kinase 10 (MAPK10) OTC46VX1 MK10_HUMAN Increases Activity [10]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN) OTOWDUNT PTEN_HUMAN Affects Localization [11]
TAR DNA-binding protein 43 (TARDBP) OTVOSFWW TADBP_HUMAN Increases Ubiquitination [12]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases Phosphorylation [5]
MAP kinase-interacting serine/threonine-protein kinase 1 (MKNK1) OTGBRJDQ MKNK1_HUMAN Increases Activity [9]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Increases Abundance [13]
Fragile X messenger ribonucleoprotein 1 (FMR1) OTWEV0T5 FMR1_HUMAN Increases Abundance [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DOT(s)
Indication(s) of Lamivudine
Disease Entry ICD 11 Status REF
Chronic HBV infection 1E51.0Z Approved [3]
Chronic hepatitis B virus infection N.A. Approved [4]
Human immunodeficiency virus infection 1C62 Approved [3]
Human immunodeficiency virus-1 infection 1C62 Approved [2]
Diarrhea ME05.1 Investigative [4]
Lamivudine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [15]
------------------------------------------------------------------------------------
Lamivudine Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [16]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [17]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [18]
------------------------------------------------------------------------------------
Lamivudine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Deoxy-5'-nucleotidase 1 (NT5C) DE4E31Z NT5C_HUMAN Metabolism [19]
Phosphorylcholine transferase A (PCYT1A) DEQYXD4 PCY1A_HUMAN Metabolism [20]
Phosphorylethanolamine transferase (PCYT2) DEIX1PO PCY2_HUMAN Metabolism [20]
------------------------------------------------------------------------------------
Lamivudine Interacts with 19 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Increases Uptake [21]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Increases Uptake [21]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Increases Expression [22]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Decreases Expression [23]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Decreases Expression [24]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [24]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Expression [25]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Expression [26]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [27]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Increases Expression [24]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Secretion [22]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [23]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Decreases Phosphorylation [22]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [23]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Increases Expression [28]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [23]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [23]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Decreases Expression [26]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Increases Uptake [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 DOT(s)

References

1 ClinicalTrials.gov (NCT02634073) A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Lamivudine FDA Label
5 A novel UBA and UBX domain protein that binds polyubiquitin and VCP and is a substrate for SAPKs. Biochem J. 2004 Dec 1;384(Pt 2):391-400. doi: 10.1042/BJ20041498.
6 Plasma concentration of iditol dehydrogenase (sorbitol dehydrogenase) in ponies treated with aflatoxin B1. Am J Vet Res. 1980 Jun;41(6):925-7.
7 Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020 May;52(5):473-481. doi: 10.1038/s41588-020-0615-4. Epub 2020 May 4.
8 Intracellular mobility and nuclear trafficking of the stress-activated kinase JNK1 are impeded by hyperosmotic stress. Biochim Biophys Acta. 2014 Feb;1843(2):253-64. doi: 10.1016/j.bbamcr.2013.10.017. Epub 2013 Nov 1.
9 The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem. 1998 Apr 17;273(16):9373-7. doi: 10.1074/jbc.273.16.9373.
10 Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. J Biol Chem. 1999 Oct 29;274(44):31150-4. doi: 10.1074/jbc.274.44.31150.
11 Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell. 2006 Sep;17(9):4002-13. doi: 10.1091/mbc.e06-05-0380. Epub 2006 Jun 28.
12 Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. J Biol Chem. 2020 Jan 17;295(3):673-689. doi: 10.1074/jbc.RA119.010617. Epub 2019 Nov 28.
13 Aldose reductase expression as a risk factor for cataract. Chem Biol Interact. 2015 Jun 5;234:247-53. doi: 10.1016/j.cbi.2014.12.017. Epub 2014 Dec 22.
14 Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor/ataxia syndrome: use of antioxidants in precision medicine. Mol Med. 2016 Oct;22:548-559. doi: 10.2119/molmed.2016.00122. Epub 2016 Jun 30.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
16 The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
17 Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos. 2012 Apr;33(3):170-8.
18 Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
19 Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 2010 Jan;85(1):39-58.
20 Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006 Aug;50(8):2686-94.
21 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
22 Nucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment. Toxicol Sci. 2013 Aug;134(2):323-34. doi: 10.1093/toxsci/kft105. Epub 2013 May 2.
23 Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
24 Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol. 2004 Sep 15;10(18):2661-5. doi: 10.3748/wjg.v10.i18.2661.
25 Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology. 2005 Nov;42(5):1028-36. doi: 10.1002/hep.20888.
26 Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001 Dec;35(6):749-55. doi: 10.1016/s0168-8278(01)00218-5.
27 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
28 Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.